# SAM #HT9427-26-R-E020

Prototype Development for Battlefield Wound Infection Prevention and Treatment Barrier Combination

**Buyer:** Defense Health Agency
**Posted:** September 23, 2026
**Respond By:** October 23, 2026
**Identifier:** HT9427-26-R-E020
**NAICS:** 541715, 541714, 325414, 339113, 339112

This opportunity is for the development of a prototype Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination product for the Defense Health Agency and U.S. Army Medical Research & Development Command.
- Government Buyer:
  - Defense Health Agency (DHA), Medical Products Warfighter Protection and Acute Care Program Management Office (WPAC PMO)
  - U.S. Army Medical Research & Development Command (USAMRDC)
- OEMs and Vendors:
  - No specific OEMs or vendors are named; open to qualified manufacturers with relevant expertise
- Products Requested:
  - Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination prototype
    - 50 final design prototypes required
    - Product must combine a physical wound barrier with antimicrobial and/or antifungal properties
    - Must achieve Technology Readiness Level (TRL) 7 by FDA submission
    - Minimum 12-month shelf life
    - Must include instructions for use
    - FDA approval or clearance required
- Services Requested:
  - Regulatory and clinical trial services
    - FDA regulatory communications
    - Chemistry, Manufacturing, and Controls (CMC) development
    - Clinical studies/trials to demonstrate safety and efficacy
    - Preparation and submission of FDA packages
    - Quality management and project reporting
- Unique/Notable Requirements:
  - Product must be suitable for battlefield use, preventing and treating wound infections
  - Must meet specific efficacy, shelf-life, and usability criteria
  - FDA approval or clearance is mandatory
  - Contract includes prototype development, clinical trials, and regulatory submissions
  - Delivery of 50 prototypes for operational test and evaluation
  - Period of performance is approximately 48 months, with overlapping objectives for development and clinical studies, followed by FDA review
- No specific part numbers or brands are listed; opportunity is open to innovative solutions from qualified manufacturers.

### Description

<p>This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency&rsquo;s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) &amp; Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.</p>

<p><br />
This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&amp;T) Barrier Combination (BC) prototype product.</p>

<p><br />
The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance).</p>

<p><br />
The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.</p>

[View original listing](https://sam.gov/opp/93963f59cd0a4b8eb1faa2e99cc77c36/view)